NasdaqCM - Delayed Quote USD
VYNE Therapeutics Inc. (VYNE)
1.8400
-0.0200
(-1.08%)
At close: April 23 at 4:00:00 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | 50k | 50k | 200k | 200k |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 100k | 100k | 400k | 400k |
| Year Ago Sales | 98k | 198k | 501k | 200k |
| Sales Growth (year/est) | -48.98% | -74.75% | -60.08% | 0.00% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -- | -0.19 | -0.23 | -0.3 |
| EPS Actual | -0.15 | -0.22 | -0.29 | -0.28 |
| Difference | -- | -0.03 | -0.05 | 0.02 |
| Surprise % | -- | -15.79% | -23.40% | 7.69% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| VYNE | -- | -- | -- | -- |
| S&P 500 | 6.85% | 4.67% | 8.41% | 14.16% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/6/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/19/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 1/14/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 1/6/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 12/23/2024 |
| Initiated | BTIG: Buy | 11/18/2024 |
Related Tickers
ATXI Avenue Therapeutics, Inc.
0.2580
-4.44%
ELTX Elicio Therapeutics, Inc.
5.22
+3.37%
ERNA Ernexa Therapeutics Inc.
0.1938
+5.21%
ELVN Enliven Therapeutics, Inc.
17.77
-1.11%
GLYC GlycoMimetics, Inc.
0.2387
+4.69%
NTHI NeOnc Technologies Holdings, Inc. Common Stock
5.88
-2.00%
HTD.MU Corcept Therapeutics Inc
60.20
+5.73%
BT3.BE Lineage Cell Therapeutics Inc
0.4020
+8.06%
7AY1.F Actinium Pharmaceuticals, Inc.
1.1160
-6.92%
HQ1.MU Oruka Therapeutics Inc. R
9.15
+0.55%